2. Search Result
Search Result
Results for "

hpk1-in-2

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132150A
    HPK1-IN-2 dihydrochloride

    		MAP4K FLT3 Src Cancer
    HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC50<0.5 µΜ) and Flt3 (IC50<0.05 µΜ) kinase activities .
    HPK1-IN-2 dihydrochloride
  • HY-168283
    HPK1 ligand 2

    		Ligands for Target Protein for PROTAC Cancer
    HPK1 ligand 2 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). HPK1 ligand 2 can be used for synthesis DD205-291 (HY-168282) .
    HPK1 ligand 2
  • HY-162544
    PROTAC HPK1 Degrader-2

    		PROTACs MAP4K Cancer
    PROTAC HPK1 Degrader-2 (compound 3) is a PROTAC degrader of HPK1, with the DC50 of 23 nM in human PBMC. PROTAC HPK1 Degrader-2 plays an important role in cancer research .
    PROTAC HPK1 Degrader-2
  • HY-162546
    3-Hydroxypropanoic acid-pip-hydroquinone-dihydrouracil

    		E3 Ligase Ligand-Linker Conjugates Cancer
    3-hydroxypropanoic acid-pip-hydroquinone-dihydrouracil is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC HPK1 Degrader-2 (HY-162544) .
    3-Hydroxypropanoic acid-pip-hydroquinone-dihydrouracil
  • HY-162545
    HPK1-IN-47

    		MAP4K Ligands for Target Protein for PROTAC Cancer
    HPK1-IN-47 is a HPK1 ligand. HPK1-IN-47 can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-2 (HY-162544). HPK1-IN-47 can be used for research of HPK1-mediated diseases including cancer .
    HPK1-IN-47
  • HY-159905
    HPK1-IN-54

    		MAP4K Inflammation/Immunology
    HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC50 value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy .
    HPK1-IN-54

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: